Background:
Contrast-sparing devices have been slowly adopted into routine patient care. Randomized trial evidence of automated contrast injectors (ACIs) has not been analyzed to evaluate the true reduction in contrast volume during coronary angiography and intervention. It has been thought that reducing the amount of contrast exposure will result in a simultaneous reduction in the risk of contrast-induced nephropathy (CIN). Therefore, we sought to synthesize published evidence on contrast-sparing devices, contrast volume, and the incidence of CIN. We searched Medline, the Cochrane Library, and Clinicaltrials.gov. The search criteria included ACIs versus manual injection, contrast media volume, and the incidence of CIN. Data were extracted by 2 independent reviewers. The weighted mean difference of contrast volume was calculated using random effects models in RevMan, version 5.4.1, software to derive a summary estimate. A total of 79,694 patients from 10 studies were included (ACI arm, n [ 20,099; manual injection arm, n [ 59,595). On average, ACIs reduced contrast volume delivery by 45 ml/case (p (p <0.001, 95% confidence interval L54 to L35). The CIN incidence was significantly reduced by 15%, with an odds ratio of 0.85 (p <0.001, 95% confidence interval 0.78 to 0.93) for those using ACIs compared with manual injection. In conclusion, the use of ACIs in angiography significantly reduces the volume of contrast delivered to the patient and the incidence of CIN.
Note: See full resource above for complete citations and references.
This document focuses on contemporary measures, including automated contrast injection (ACI) systems, to prevent contrast-induced nephropathy (CIN) following catheterization and percutaneous coronary intervention (PCI). The use of automated contrast injection systems, such as the ACIST CVi® Contrast Delivery System, can effectively decrease the volume of contrast used during procedures. It remains uncertain whether lower contrast volume is associated with a reduced incidence of CIN; however, a trial was conducted at Wake Forest University Medical Center involving 1,798 patients who underwent diagnostic catheterization or PCI using handheld manifold injection systems, followed by 377 subsequent patients utilizing an automated contrast injection system. The study’s findings demonstrate that when combined with contemporary hydration and pharmacologic strategies, the use of an automated contrast injection system significantly reduces both contrast volume and the incidence of CIN. For further details on ACIs, such as CVi®, and their positive impact on mitigating contrast-induced nephropathy, continue reading.
Study Objectives: To evaluate the incidence of contrast-induced nephropathy (CIN) with the use of an automated contrast injection system in conjunction with contemporary measures to prevent CIN after cardiac catheterization and percutaneous coronary intervention (PCI).
Background: The use of automated contrast injection systems can reduce the volume of procedural contrast, but whether lower contrast volume is associated with lower incidence of CIN is uncertain
Note: See full resource above for complete citations and references.
Join a conversation with Dr. Bob Wilson, founder of ACIST Medical Systems, about the ACIST CVi® Contrast Delivery System. ACIST CVi® System is an automated, variable-rate contrast injection system for angiographic procedures. Some key features of the CVi® mentioned are the variable rate injection controlled by the handheld AngioTouch®, 4 active safety sensors, peristaltic pump for saline delivery, and integrated hemodynamic monitoring from the catheter. Dr. Wilson mentions how CVi® uses pressure to achieve the desired flow rate selected, and how the limit can be set by the operator on the CVi® monitor. Pressure works closely with flow rate, which is the volume of fluid delivered in a specified amount of time. Read on to learn more about ACIST CVi® Contrast Delivery System and valuable insights regarding flow rate parameters and pressure.
Background of Bob Wilson, MD:
Clinical Chief, Cardiovascular Division, University of Minnesota, Dr. Bob Wilson has spent decades focusing on the development of medical, devices for the diagnosis and treatment of cardiovascular diseases. His research into methods for studying the coronary circulation in humans led to the development of the first coronary Doppler catheter to measure coronary blood flow, one among many contributions to science and biomedical engineering projects. He was Founder and Chairman of the Board of Directors of ACIST Medical systems, which now markets a range of devices in 44 countries worldwide.
Note: See full resource above for complete citations and references.
